-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Honored as One of the Top 100 Pharmaceutical Companies by Revenue and Among the Top 50 Enterprises for Independent Innovation in the Pharmaceutical Industry for the 2024–2025 Period
Category:
发布时间：2025-11-11
【概要描述】
On November 10, the “Fourth Taishan Pharmaceutical Forum and the 2024–2025 Pharmaceutical Industry Information Release Conference,” hosted by the Organizing Committee of the Taishan Pharmaceutical Forum, was held in Jinan. During the event, a series of rankings were unveiled, including the Top 100 Pharmaceutical Companies by Operating Revenue for the 2024–2025 period. Shijiazhuang Sihua Pharmaceutical Group was honored with two prestigious awards: being named among the Top 100 Pharmaceutical Companies by Operating Revenue and among the Top 50 Enterprises for Independent Innovation in the Pharmaceutical Industry.
On November 10, the “Fourth Taishan Pharmaceutical Forum and the 2024–2025 Pharmaceutical Industry Information Release Conference,” hosted by the Organizing Committee of the Taishan Pharmaceutical Forum, was held in Jinan. During the event, a series of rankings were unveiled, including the Top 100 Pharmaceutical Companies by Operating Revenue for the 2024–2025 period. Shijiazhuang Sihua Pharmaceutical Group was honored with two prestigious awards: being named among the Top 100 Pharmaceutical Companies by Operating Revenue and among the Top 50 Enterprises for Independent Innovation in the Pharmaceutical Industry.
Over the past two years, the Group has remained firmly committed to high-quality development as its top priority, taking it as its mission to research, develop, and produce more “Made-in-China” pharmaceuticals. Grounded in national strategies and market demands, the Group has vigorously implemented an innovation-driven strategy, relentlessly pursuing innovation with a sense of urgency and momentum. It has continuously promoted the deep integration and coordinated development of the innovation chain, talent chain, industrial chain, and supply chain, accelerating the establishment of a modern industrial system that is led by innovative drugs, underpinned by specialty chemical drug formulations and active pharmaceutical ingredients, and extended by high-end pharmaceutical packaging materials and distinctive biologics. In doing so, the Group has consistently fostered and developed new drivers of productivity, while leveraging technological innovation and digital transformation to power the integrated development of “APIs plus formulations.” The Group’s number of applications submitted and approvals obtained continues to rank among the industry leaders, with a cumulative total of 156 drug varieties and 207 dosage forms having either passed or been deemed to have passed the evaluation of generic drug quality and therapeutic equivalence. As a result, the foundation for the company’s innovative, high-quality development has grown ever stronger, and its innovative influence and market competitiveness have achieved a new leap forward.
According to reports, the Taishan Pharmaceutical Forum has been successfully held for four consecutive sessions to date. As a key platform for intellectual exchange and industrial collaboration within China’s pharmaceutical sector, this year’s forum further reinforces its core positioning of “whole-industry, large-scale platform, deep integration, and shared development,” thereby promoting the efficient connection of industry resources and driving innovation and upgrading. Together, these efforts are aimed at building a comprehensive, full-chain business cooperation platform that enables win-win development for all participating enterprises.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091